Male Contraception
11
2
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (11)
A First in Human Study, Evaluating the Safety and Efficacy of ADAM™ 1.0
Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)
Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males
28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men